

PHARMACY POLICY STATEMENT

North Carolina Marketplace

DRUG NAME	Nucala (mepolizumab)
BENEFIT TYPE	Medical or Pharmacy
STATUS	Prior Authorization Required

Nucala is an interleukin-5 (IL-5) antagonist monoclonal antibody (IgG1 kappa) first approved for the treatment of severe eosinophilic asthma in 2015. Since that time, it has been approved for three additional indications - eosinophilic granulomatosis with polyangiitis (EGPA), hypereosinophilic syndrome (HES), and chronic rhinosinusitis with nasal polyps (CRSwNP). All four indications are eosinophilic-driven disease states. Nucala works by blocking IL-5 binding to the alpha chain of the IL-5 receptor complex. This inhibits IL-

	applicable in clinical trial setting) and replaced with no GPA, MPA, or life threatening EGPA; removed hx of alcohol/substance abuse; changed initial approval period from 12 months to 6 months.
10/29/2021	New indication of CRSwNP added. Changed to new format.
11/02/2022	CRSwNP

23. Bachert C, et al. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management. *J Allergy Clin Immunol.* 2021;147(1):29-36
24. Han JK, Bachert C, et al. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet.* 2021; 9(10):1141-1153.

Effective date: 04/01/2024

Revised date: 11/27/2023